Figure 1
From: Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
Observed changes in CA 15-3 levels in patients with stable disease ≥ 6 months from baseline to 6th treatment (n = 28).
Figure 1 | BMC Cancer